KNSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KNSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kiniksa Pharmaceuticals International's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.18. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.14.
Kiniksa Pharmaceuticals International's EPS (Basic) for the three months ended in Sep. 2024 was $-0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.13.
Kiniksa Pharmaceuticals International's EPS without NRI for the three months ended in Sep. 2024 was $-0.18. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.14.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 8 years, Kiniksa Pharmaceuticals International's highest 3-Year average EPS without NRI Growth Rate was 13.00% per year. The lowest was -59.40% per year. And the median was -9.30% per year.
The historical data trend for Kiniksa Pharmaceuticals International's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EPS (Diluted) | Get a 7-Day Free Trial | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 |
Kiniksa Pharmaceuticals International Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EPS (Diluted) | Get a 7-Day Free Trial | -0.20 | 0.35 | -0.25 | -0.06 | -0.18 |
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's PE Ratio distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Kiniksa Pharmaceuticals International's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
Diluted EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (14.084 | - | 0) | / | 71.923 | |
= | 0.20 |
Kiniksa Pharmaceuticals International's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as
Diluted EPS (Q: Sep. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-12.693 | - | 0) | / | 71.727 | |
= | -0.18 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (NAS:KNSA) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Ragosa | officer: Interim CFO | C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421 |
Michael R Megna | officer: Chief Accounting Officer | 1050 HINGHAM STREET, ROCKLAND MA 02370 |
Eben Tessari | officer: Chief Business Officer | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Sanj K Patel | director, 10 percent owner, officer: Chairman & CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Ross Moat | officer: Group VP & Rilonacept GM | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
John Paolini | officer: Chief Medical Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Barry D Quart | director | C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549 |
Felix Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Arian Pano | officer: Chief Clinical Dev. Officer | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas W. Beetham | 10 percent owner, officer: Chief Legal Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
G Bradley Cole | director | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
From GuruFocus
By Marketwired • 11-12-2024
By GuruFocus News • 10-30-2024
By Marketwired • 07-09-2024
By Marketwired • 10-01-2024
By GuruFocus News • 11-15-2024
By Marketwired • 10-28-2024
By GuruFocus Research • 07-24-2024
By GuruFocus News • 10-29-2024
By GuruFocus News • 10-28-2024
By GuruFocus Research • 07-24-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.